

MOU

Manipal Institute of Virology

And

SCEs Indira College of Pharmacy

MOU

This MEMORANDUM OF UNDERSTANDING (hereinafter referred to as "AGREEMENT") is made and entered into as on the 15th day of March, 2022 and deemed to be effective from 1st day of APRIL, 2022 ("EFFECTIVE DATE") by and between:

Manipal Academy of Higher Education (MAHE), a deemed to be University under Section 3 of UGC Act, 1956, having its registered office at Madhav Nagar, Manipal - 576104, Karnataka, India, on behalf of **Manipal Institute of Virology** (hereinafter referred to as "**MIV**"), a constituent unit of MAHE, and represented by its Registrar, Dr. Narayana Sabhahit, hereinafter referred to as the **FIRST PARTY**

AND

SCES's Indira College of Pharmacy (ICP), established under the aegis of Savitribai Phule Pune University, having its office at Ganeshkhind Pune, Maharashtra 411007 and represented by its **Principal, Dr. Anagha Joshi** hereinafter referred to as the **SECOND PARTY**

Whereas -

- A. MIV, a constituent unit of the First Party, is a center for training, education and research in virology with the state-of-the-art laboratory. Antiviral testing services is a platform to support the research related activities of interested academic and industrial collaborators.
- B. Both parties wish to enter into an Agreement wherein the First Party, through its constituent unit MIV, shall provide testing facility on a nominally charged basis for the assessment of *in vitro* cytotoxicity and *in vitro* antiviral activity of the test samples provided by the Second Party. These charges are mainly towards the cost of consumables, required for the execution of the experiments involved.
- C. Both parties are higher education institutions with full legal capacity to establish commitments, and whose mission includes providing quality learning opportunities for its students and communities, as well as promoting academic research;
- D. Both parties having the facility and objective to undertake research activity, have the required infrastructure, personnel and research minded employees with right aptitude,
- E. Both the institutions have agreed to carry out research projects with special emphasis on antiviral drug discovery and development.

Now, Therefore, in consideration of mutual agreements, covenants, representations and warranties set forth in this Agreement, the Parties hereby agree to the following clauses,



- 1) The Commencement Date of this Agreement shall be 1st day of APRIL, 2022. This Agreement shall be valid for a period of 3 (three) years from the Commencement Date.
- 2) This agreement shall establish the criteria under which MAHE and ICP will carry out joint collaborative activities of mutual interests, particularly in the field of antiviral drug discovery and development to improve quality of research and build the capabilities of their students and faculty members.
- 3) Both the parties agree to share their expertise for academic and research collaborations of mutual interests.
- 4) The parties may, jointly or separately, endeavor to obtain financial resources from other institutions, government agencies and national and international organizations for the development of activities associated with the implementation of any Specific Agreement.
- 5) Both parties agree that any of the laws and rules laid down by MAHE, ICP, State Government, Central Government, UGC and appropriate regulatory authorities will be strictly adhered to and its change that may occur time to time in future are followed.
- 6) The parties shall perform the research studies in compliance with (i) the Agreement (ii) the drafted Protocols, (iii) approval of institutional review board / institutional ethics committee (IEC), and (iv) generally accepted laboratory and pharmacological practices as recommended in their latest guidelines of Institutional Bio-Safety committee (IBSC), Department of Biotechnology-India (DBT) and Indian Council of Medical research (ICMR, MoHFW, Govt. of India)
- 7) Both the parties share the rights to use the data and results generated from their collaborative study; for their internal research, educational (including teaching) purposes, publication and/or presentation in any reputed journal and/or conference, patents with receiving due acknowledgment from the other Party.
- 8) Both the parties agree to publish the results irrespective of whether it is positive or negative and that they include each other's name with prior consent from the other party.
- 9) The parties agree to maintain the confidentially on information related to the cooperative activities such as financial, scientific, corporate, industrial, product and business information disclosed by the other Party and/or its Affiliates and any and all results, information, data and documents generated, produced or obtained.
- 10) The list of antiviral screening tests with respective codes and charges is enclosed (Please refer **Annexure A**). The rate list shall be valid for 1 (one) year from the date of commencement and 18% GST shall be charged EXTRA by MAHE as per the prevailing tax norms.
- 11) If the Second Party agrees to include the First Party as co-authors in any related scientific publications or share the rights of any intellectual property generating out of this work, a discounted rate as mentioned in Annexure A, may be applied to cover only the working costs involved.



- 12) The test samples shall be packed and dispatched by the Second Party and collected by the First Party. The First Party shall not be responsible for any damage or loss of the test samples caused due to oversight/negligence during dispatch or in transit. The responsibility to pack and dispatch the samples on time, shall lie with the Second Party.
- 13) The budget for the experimental expenditures will be prepared by the First Party depending on the number of test samples requested for antiviral testing by the Second Party.
- 14) Billing shall be done by the First Party and a statement/Invoice for payment, once ready will be sent to the Second Party. Payments shall be made within **10 days** of receipt of the statement.
- 15) Depending upon the standard testing procedure and time required for performing the test, the First Party shall send the reports of the test samples by email to the Second Party.
- 16) The First Party shall not be responsible for any delays resulting from infrastructural break down or any other specific issues that prevent from undertaking the test which are out of control of the management of the First Party.
- 17) The First Party shall be conducting all the tests following standardized laboratory protocols and will be responsible for the authenticity of the test results. In case of any disagreements from the Second Party regarding outcome of the results obtained, the First Party should not be held responsible.
- 18) The present Agreement will become valid upon signature by both parties and shall remain in effect for a period of three years from its effective date. The agreement may be amended at any time by a written agreement signed by authorized representatives of both parties.
- 19) **Termination of the Agreement:** Termination of the Agreement may be effected by a notice, in writing, **1 (one) month** prior, by either Party. If the Second Party wishes to terminate the Agreement, they shall inform the First Party in writing, about the intention to discontinue the Agreement and clear all outstanding amount. However, in any circumstances the paid amount shall not be refunded.
- 20) In case of continuance of the collaborative work, after completion of the term of the Agreement, a renewal for extension is mandatory.
- 21) This Agreement shall be governed by Indian Laws and in case of any disputes, it shall be resolved amicably by the Parties, primarily through mediation between the Chief Executives of the two organizations.



In Witness Whereof, each Party to this Agreement has caused it to be executed by its duly authorized representative as of the Commencement Date.

For and on behalf of

Manipal Academy of Higher Education, Manipal



Sabhaht

Name: Dr. Narayana Sabhaht
Title: Registrar

For and on behalf of

Indira College of Pharmacy, Pune

Anagha Joshi

Name: Dr. Anagha Joshi
Title: Principal

For and on behalf of

Manipal Institute of Virology, Manipal

Chiranjay Mukhopadhyaya

Name: Dr. Chiranjay Mukhopadhyaya
Title: Director, MIV, MAHE

For and on behalf of

Indira College of Pharmacy, Pune

Madhur Kulkarni

Name: Dr. Madhur Kulkarni
Title: Associate Professor
& HOD- Pharmaceutics

ANNEXURE A
CYTOTOXICITY/ANTIVIRAL SCREENING PANEL

RATE LIST FOR ACADEMIC COLLABORATORS			
CODE	CATEGORY & TEST	PRICE (INR)	DISCOUNTED PRICE (INR)
VIRS008	Cytotoxicity assessment per test sample per cell line	5000	3000
VIRS009	Antiviral screening against Herpes simplex virus 1- post-infection treatment with each test sample	10000	6000
VIRS010	Antiviral screening against Herpes simplex virus 1- pre-infection treatment with each test sample	10000	6000
VIRS011	Antiviral screening against Herpes simplex virus 1- simultaneous treatment with each test sample	10000	6000
VIRS012	Antiviral screening against Herpes simplex virus 2- post-infection treatment with each test sample	10000	6000
VIRS013	Antiviral screening against Herpes simplex virus 2- pre-infection treatment with each test sample	10000	6000
VIRS014	Antiviral screening against Herpes simplex virus 2- simultaneous treatment with each test sample	10000	6000
VIRS015	Antiviral screening against Influenza A(H1N1) pdm09 virus- post-infection treatment with each test sample	10000	6000
VIRS016	Antiviral screening against Influenza A(H1N1) pdm09 virus- pre-infection treatment with each test sample	10000	6000
VIRS017	Antiviral screening against Influenza A(H1N1) pdm09 virus- simultaneous treatment with each test sample	10000	6000



SUMMARY



Shree Chanakya Education Society's
Indira College of Pharmacy, Pune

"Redefining Pharmacy Education"

NAAC: B++

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU & MSBTE, Recognized by Govt. of Maharashtra

SUMMARY

A project proposal has been submitted collaborately for the seed grant to Manipal Institute of Virology.



Dr. Anagha M Joshi

PRINCIPAL

**Indira College of Pharmacy
Tathawade, Pune - 411 033**

Collaborative Project



Shree Chanakya Education Society's
Indira College of Pharmacy, Pune
"Redefining Pharmacy Education"

NAAC: B++

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU & MSBTE, Recognized by Govt. of Maharashtra

Project Title:

Screening of two drug formulations (Tenofovir disoproxil fumarate and Zinc acetate dihydrate) and their combination for pre-exposure prophylaxis and treatment of Herpes Simplex Virus-2 (HSV-2) infections

Principal Investigator:

Dr Piya Paul Mudgal, Associate Professor, Manipal Institute of Virology

Co-Principal Investigator:

Dr. Madhur Kulkarni, Associate Professor, Indira College of Pharmacy

Grant details:

Seed grant of INR 1 Lakh applied to Manipal Institute of Virology for interdisciplinary research of 1 year duration




PRINCIPAL
Indira College of Pharmacy
Tathawade, Pune - 411 033